Altimmune Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2834 https://altimmune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune Inc

Altimmune to Participate in Upcoming Investor Conferences - Oct 10th, 2019 11:00 am
Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer - Sep 9th, 2019 11:00 am
Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield™ Clinical Development - Aug 21st, 2019 11:00 am
Altimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update - Aug 13th, 2019 8:15 pm
Altimmune to Announce Second Quarter 2019 Financial Results on August 14 - Aug 5th, 2019 11:00 am
Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc. - Jul 15th, 2019 11:00 am
Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio - Jul 9th, 2019 12:48 pm
Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio - Jul 9th, 2019 11:00 am
Altimmune Appoints Will Brown as Chief Financial Officer - Jun 12th, 2019 12:00 pm
Altimmune Announces Successful Pre-IND Meeting with FDA - Jun 10th, 2019 12:00 pm
Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs - Jun 5th, 2019 12:00 pm
Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update - May 14th, 2019 8:15 pm
Altimmune to Announce First Quarter 2019 Financial Results on May 15 - May 8th, 2019 12:00 pm
Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C. - Apr 11th, 2019 1:27 pm
Altimmune, Inc. to Host Earnings Call - Apr 2nd, 2019 10:30 am